England’s National Health Service has announced a commissioning framework which establishes a best value first approach for biological medicines, including biosimilars.
The revised framework builds on previous efforts to “support integrated care boards and providers to act promptly to secure savings...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?